Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...

The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor shot. Moderna said its own vaccine, dubbed ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of adverse events from a 2b/3 trial of its lead candidate bexotegrast. Back in ...

Turnstone Biologics has limped to the exit. Xoma Royalty is buying Turnstone for less than $8 million, marking a low-profile ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Embattled CytoDyn and key ex-executives must face an investor lawsuit claiming the company knowingly misled shareholders ...

Cosmo Pharmaceuticals aims to make the colonoscopy a little more up close and personal, for providers anyway, by connecting ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...